Full Text View
Tabular View
No Study Results Posted
Related Studies
Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients
This study is ongoing, but not recruiting participants.
Study NCT00024557   Information provided by Neopharm
First Received: September 20, 2001   Last Updated: June 23, 2005   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Malignant Glioma
Glioblastoma Multiforme
Anaplastic Astrocytoma
Mixed Oligoastrocytoma
Malignant Astrocytoma
Additional conditions recognized in this trial
Astrocytoma
Glioblastoma
Glioma
Oligodendroglioma
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Interventions listed in this trial
IL13-PE38QQR
targeted fusion protein therapy
surgery
Sponsors listed in this trial
Neopharm


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services